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To the Editor, 
Loss of function or null mutations of Stromal interaction molecule 1 (STIM1) 
are known to cause early-onset combined immunodeficiency (CID) disease with 
recurrent and chronic infections, autoimmunity, haemolytic anaemia, ectodermal 
dysplasia, muscular weakness and myalgia (1). STIM1 and ORAI1 form the calcium 
release-activated calcium (CRAC) channels and are involved in calcium signalling, 
which is especially important in T cells for activation, proliferation and cytokine 
production (2). ORAI1 forms the pore in the plasma membrane and STIM1 is a 
calcium sensor protein that activates the ORAI1 when the endoplasmic reticulum 
(ER) Ca2+ stores are depleted. 
STIM1-deficient patients have impaired T cells and NK cell function, but 
usually a normal distribution of the major immune cell types, including T cells, B cells 
and natural killer (NK) cells with the T cell repertoire that is normally comparable to 
healthy individuals (3). STIM1 deficiency results in no store-operated calcium entry 
(SOCE) in T cells and as a result the patient’s cells cannot respond appropriately to 
T cell receptor (TCR) activation or pharmacological agents such as ionomycin, 
thapsigargin (TG), which typically trigger Ca2+ influx (1).  
Recently a new biological role for STIM1 has been identified. STIM1 was 
found to act as a negative regulator for STimulator of INterferon Genes (STING). 
STIM1 was shown to inhibit STING trafficking by physically interacting with STING 
and retaining it at the ER membrane. This interaction is important in maintaining 
STING in an inactive state (4). Several STING mutations which have previously 
shown to cause an autoinflammatory condition named STING-associated 
vasculopathy with onset in infancy (SAVI), appear to exert their dominant effects by 
weakening the interaction between STIM1 and STING (4).   
Here we describe a 5-year-old boy of consanguineous Pakistani background 
with overlapping clinical features of CID and autoinflammatory disorder. The boy was 
initially referred to pediatric immunology services with a history of recurrent 
sinopulmonary infections. The patient was born at full term by normal vaginal 
delivery following a normal pregnancy. An inguinal hernia was noted when six days 
old and was repaired the same day.  He initially fed well. At six months of age it was 
noted that he was quieter and delayed in his development. He sat at 18 months and 
walked at 3 years and crawls upstairs using his head as support. Currently, at 5 
years he is alert and engaging but has speech delay putting 2-3 words together.  He 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
can scribble and draw circles.  He was fully toilet-trained at 3 years. He is in 
mainstream education but requires additional support. 
When examined at 5 years, he weighed 11.5kg (-5SD), with a height of 
94.2cm (-4SD) and head circumference of 46.1cm (-4SD). He is slim, with reduced 
proximal upper limb muscle bulk and globally in his lower limbs, lordosis and is 
hypermobile across all his joints. He has proximal weakness leading to a waddling 
gait, and uses a Gowers manoeuvre to stand. He has no facial weakness, no 
opthalmoparesis but has fixed dilated pupils.  
The patient infection history included recurrent sinopulmonary infections with 
one episode of pneumonia requiring hospital admission and intravenous antibiotics. 
He had received all his primary vaccinations, including MMR, without significant 
complications. He was hospitalized for a complicated primary varicella zoster 
infection due to bacterial suprainfection requiring antibiotic treatment. In addition, he 
had several hospitalizations with suspected infections, but despite having 
documented fevers, no apparent infective cause was found and on several 
occasions, he recovered without receiving antibiotics.  A full dental clearance was 
performed due to recurrent tooth infections and tooth enamel deficiency. Other 
characteristics include, ichthyosis, anhidrosis and low zinc levels [7.8 mol/l 
(reference range 10.3-18.1)]. Although he was described to have severe eczema his 
skin eruptions mainly affected the palms, soles of the feet and cheeks, (cold exposed 
areas), and would start with blistering sterile pustular psoriasiform rash, eventually 
resulting in skin desquamation. Zinc replacement did not lead to improvement, and 
there was minimal benefit from application of topical steroid.  The patient also had 
pronounced nail dystrophy (Figure 1). There was no history of Raynaud’s 
phenomena.  
He has two other siblings who are fit and healthy. The pedigree is shown in 
Figure 2A.  
The initial investigations including full blood count, creatinine kinase, screen 
for inherited metabolic diseases and MRI scan of the head were all normal. The 
immunological work up showed essentially normal numbers of T, B and NK cells. 
More detailed phenotyping revealed, detectable regulatory T cells and unremarkable 
memory B cell profile. Immunoglobulin profile (IgG, IgA, IgM and IgG subclasses) 
was normal with marginally elevated total IgE. The levels of specific antibodies to 
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tetanus and Haemophilus influenzae type b (Hib) were adequate and showing a 
good response to previous vaccination. Interestingly, the total anti-pneumococcal 
antibody levels were reduced, however, following a challenge vaccination with 
pneumovax, the levels increased well above the protective titre (from 6.2 to 120.7 
g/ml)
Considering some of the clinical features, diagnosis of STIM1 or ORAI1 
deficiency was suspected. The parents consented for genetic testing. A modified 
exome sequencing approach was performed using Agilent SureSelectXT with All 
Exon v5 capture library and sequenced on Illumina HiSeq 3000 for 2x150-bp paired-
end sequencing. Genetic testing identified a homozygous deletion in STIM1 
NM_003156.3:c.478del, p.(Ser160ValfsTer15), and a homozygous CANT1 mutation 
NM_001159772.1:c.676G>A, p.(Val226Met) (Figure 2A). This known pathogenic 
CANT1 mutation has previously been described in multiple patients with “Kim-
variant” Desbuquois dysplasia, usually in compound heterozygosity with another 
mutation (5,6). These patients have normal clinical examination but advanced carpal 
age, elongated phalanges and short metacarpals on radiological examination.  Only 
one patient, reported to have “Kim-variant” Desbuquois dysplasia, was homozygous 
for the CANT1 c.676G>A mutation but little phenotypic information was provided 
(5,6). The same homozygous mutation has also been described in a single patient 
with autosomal recessive multiple epiphyseal dysplasia (7).  That patient did not 
have many of the features of “Kim-variant” Desbuquois dysplasia but had developed 
the degenerative arthrosis of the hands and spine by the age of 25 years. 
The novel single nucleotide deletion at c.478 in STIM1 results in a frameshift 
such that translation terminates prematurely within the sterile alpha motif (SAM), the 
region regulating stability within STIM proteins. The truncated polypeptide of 173 
amino acids (wild type STIM1 polypeptide has several splice variants, one of which 
is 791 amino acids, another form is 685) lacks important functional domains of 
STIM1, including the transmembrane region and the CRAC activation domain (CAD). 
We used western blot to investigate the expression of STIM1 in the patient’s (P1) 
PBMCs, and failed to detect either the full length or the truncated variant of STIM1. 
However, we did detect expression of STIM2, a homologue of STIM1. The former 
was not expressed in PBMCs from HC (Figure 1B). 
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 The functional impact of these mutations was investigated further. Regarding 
the STIM1 variant we performed flow cytometry T receptor spectraphenotyping and 
showed essentially normal TCR repertoire (Figure 1 Suppl). A single Vb region 
(Vb7.2) was missing from patient’s T cells, however the clinical significance of this is 
unknown. Proliferative responses to Phytohaemagglutinin (PHA) were adequate 
(although reduced at high concentrations) and the response to anti-CD3 was 
preserved (Figure 2A Suppl).  There was significantly reduced upregulation of CD25 
following anti-CD3 in-vitro stimulation whilst upregulation of HLA-DR and CD69 was 
normal (Figure2B suppl). Measurement of store-operated Ca2+ entry in patient T 
cells revealed a complete lack of calcium influx in response to anti-CD3/anti-CD28 
stimulation and TG, as seen in Figure 2C.  
A skeletal survey was performed to investigate the impact of the CANT1 
variant on the patient’s phenotype. His overall small stature was consistent with 
previous reports regarding the effects of this CANT1 variant. His skeletal survey 
revealed the abnormal early maturation of carpal bones seen in CANT1-related 
disorders.  It also showed a gentle curve scoliosis of the cervicothoracic spine, which 
is in keeping with CANT1-related disorders.  The skeletal survey did not convincingly 
demonstrate the so-called monkey-wrench deformity of the femoral necks, shortened 
metacarpal bones, and other abnormalities which have previously been described in 
patients with Desbuquois dysplasia (8,9) (Figure 3).  Some of the radiological 
features are progressive and may appear at a later date but the skeletal phenotype 
is more in keeping with the patient described as having MED (7).  That patient was 
also homozygous for the CANT1 c.676G>A and it has already been proven that this 
mutation significantly reduces, but does not eliminate, the nucleotidase activity of 
CANT1(5).  In comparison, most patients described as having “Kim-variant” 
Desbuquois dysplasia have this mutation alongside a second mutation anticipated to 
cause a premature stop codon or shown to cause more significantly reduced CANT1 
nucleotidase activity (5).   As has already been hypothesised, it is likely that 
homozygosity for the p.(Val226Met) mutation in CANT1 causes a less severe 
phenotype than the “Kim-variant” Desbuquois dysplasia (7), which occurs when a 
more damaging mutation is present on the other allele. 
 We have previously reported two other cases with a homozygous mutation in 
STIM1, resulting in impaired store-operated calcium entry, reduced natural killer and 
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T cell function, but without overt clinical immunodeficiency (10) (Table 1). We 
arranged a follow up visit to assess their clinical progress and repeat immunological 
assessment following their initial investigations in 2012. From the immunological 
perspective, 6 years later, both cousins were generally well and had not suffered 
from any serious, frequent or opportunistic infections.  They both continued to 
experience some problems with anhydrosis and mild muscle weakness but were 
otherwise unaffected by their condition. They did not report any new symptoms. 
Repeat immunological assessment showed that V:3 (older cousin as designated in 
the original publication) had persistent CD8 lymphopenia (8%, 86 cells/l), new mild 
B cell lymphopenia (88 cells/l) (ref: 100-500 cells/l), but also normal 
immunoglobulin profile with adequate levels of specific antibodies to Hib, tetanus and 
pneumococcus. Furthermore, repeated PHA and anti-CD3 T cell stimulation 
indicated normal responses. TCR repertoire, assessed by T receptor 
spectraphenotyping, showed no abnormalities. The results of the tests on the second 
cousin (V:2) are shown in Table 1. These are essentially unchanged apart from the 
anti-nuclear antibody test which on this occasion was negative. 
We have previously shown that monocytes and peripheral blood mononuclear 
cells (PBMCs) from the patient (P1) with the novel STIM1 deletion mutation have 
significantly increased interferon-stimulated gene (ISG) expression compared to 
healthy controls (HC) (4). This was consistent with expected loss of STIM1-mediated 
STING inhibition (4). We wanted to check if this STIM1 function is also affected in 
patients harboring p.L74P STIM1 variant. We obtained blood from the patient (V:2) 
and PBMCs were separated by gradient separation using Lymphoprep (Stem Cell 
Technologies) and monocytes were purified from PBMCs using a monocyte 
separation kit II (# 130-091-153, Miltenyi Biotec). The ISG expression was measured 
using TaqMan probes (for details please see supplements). While ISG expression in 
PBMCs and monocytes from V:2 was reduced compared to what we previously have 
shown for P1(4) there was significant increase in several ISG compared to HC, 
suggesting that the p.L74P variant has effect on STIM1-mediated STING inhibition 
(Figure 4). We have previously shown that overexpression of p.L74P variant in 
HEK293 cells results in preferential localization of the mutated protein to puncta 
rather than the ER (10). Using Western blot and two sets of anti-STIM 1 antibodies 
(one specific for the N-terminal and the other for protein C-terminal, for details please 
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see supplements) we failed to detect any STIM1 expression in V:2 PBMCs. This 
suggest that p.L74P mutation under physiological conditions affects the protein 
stability, resulting in reduced expression, and therefore reduced inhibition of STING.  
The new patient we describe in this report has two monogenic conditions, 
STIM1 deficiency and CANT1-related disorder. However, most of the clinical 
manifestations are due to STIM1 deficiency. The CANT1 variant will be responsible 
for the short statue, mild scoliosis and advanced carpal age but other features such 
as premature arthritis may develop with time. On the other hand, the nature of 
genetic defect found in STIM1 is more severe (deletion compared to amino acid 
substitution in CANT1) and the non-immunological features typically associated with 
STIM1 deficiency (anhydrosis, amelogenesis imperfecta and muscle weakness) are 
fully expressed. Furthermore, biochemical studies of the new STIM1 variant, clearly 
showed loss of expression of full length STIM1 (4).  
STIM 1 deficiency is still quite rare, however with increasing number of cases 
being reported world-wide a more complete picture of the clinical phenotypes 
associated with this disorder is beginning to emerge.  The homozygous mutations 
resulting in amino acid substitution and total lack of protein expression have both 
been described. Although there are too few cases to determine if there is genotype-
phenotype correlation in this condition (Table 2), the only fatalities associated with 
STIM1 deficiency have only been reported with the mutations resulting in total loss of 
the protein expression (LOE) (1,11,12), however, SCID-like phenotypes have been 
described in patients where STIM1 mutations lead to loss of function without LOE 
(12,15).  
The non-immunological features of the case we report here overall fit with the 
classical STIM1 deficiency due to enamel deficiency, anhydrosis and muscle 
weakness; but the mild immunological phenotype, in a patient lacking full length 
STIM1 expression is a novel presentation. Furthermore, this patient has several 
clinical features suggestive of autoinflammatory complications. Although he does not 
have pulmonary involvement (fibrosis) or severe ulceration and necrosis of the skin, 
which are typical for SAVI, he did have pustular rash developing at the cold exposed 
areas of the skin and acral surfaces, which have been reported in this condition (16). 
He also had a history of unexplained fevers, however, to an extent, this could be 
explained by anhydrosis. Interestingly, patient V:2, who also has increased ISG, 
does not have any clinical features to suggest autoinflammatory condition. 
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Therefore, the effect of SAVI disinhibition in STIM1 deficiency on clinical phenotype 
is complex and difficult to predict. Nevertheless, overlap between PID and systemic 
autoinflammatory disorders is increasingly being recognized, and this case adds to 
this growing disease area. 
 There are scant long-term outcome data for patients with STIM1 deficiency. 
The patients we reported first in 2012 and reinvestigated now in 2018 have not 
seemingly developed any overt immunological problems and reassuringly the repeat 
investigations of their immune system do not show any significant deterioration. It is 
interesting that lack of calcium flux seen in the patients’ T cells, either due to total 
lack of full length STIM 1 expression or due to truncated STIM1, has not resulted in a 
more profound immunodeficiency. We assume that a form of compensatory 
mechanism must be in place to account for this outcome. One possibility is that other 
related proteins such as STIM2, a homologue of STIM1, might provide this role. 
Indeed, when we examined expression of STIM2 in PBMCs from P1 and V:2, the 
expression of the protein was increased compared to HC, in fact HC PBMCs did not 
show any expression of STIM2 under resting conditions. In addition, high interferon 
drive was detected in both STIM1 deficient cases, and this might offer some 
protection against viral pathogens. Lastly, considering immunological and non-
immunological features of STIM1 deficiency, this condition should be thought of as 
another form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), 
similarly to what has recently been proposed for ORA1 deficiency (17). 
Disclosure of potential conflict of interest: The authors declare that they have no 
relevant conflicts of interest. 
Acknowledgements 
This research is supported by grant from CSL Behring and by the National Institute 
for Health Research (NIHR) Leeds Biomedical Research Centre. The views 
expressed are those of the author(s) and not necessarily those of the NHS, the NIHR 
or the Department of Health. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Reference 
1. Picard C, McCarl C-A, Papolos A, et al. STIM1 Mutation Associated with a Syndrome of 
Immunodeficiency and Autoimmunity. The New England journal of medicine. 
2009;360(19):1971-1980. doi:10.1056/NEJMoa0900082. 
 
2. Feske S, Prakriya M, Rao A, Lewis RS. A severe defect in CRAC Ca2+ channel activation and 
altered K+ channel gating in T cells from immunodeficient patients. The Journal of 
Experimental Medicine. 2005;202(5):651-662. doi:10.1084/jem.20050687. 
 
3. Feske S, Picard C, Fischer A. Immunodeficiency due to mutations 
in ORAI1and STIM1. Clinical immunology (Orlando, Fla). 2010;135(2):169-182. 
doi:10.1016/j.clim.2010.01.011. 
 
4. Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, Rice L, Seo GJ, Calmettes 
G, Ramakrishna C, Cantin E, An DS, Sun R, Wu T-T, Jung JU, Savic S, Gwack Y.  STIM1 
regulates type I interferon response by retaining STING at the endoplasmic reticulum. Nat 
Immun 2018- accepted for publication   
 
5. Furuichi T, Dai J, Cho T, et al, CANT1 mutation is also responsible for Desbuquois dysplasia, 
type 2 and Kim variant, Journal of Medical Genetics 2011;48:32-37. 
doi:10.1136/jmg.2010.080226 
 
6. Kim OH, Nishimura G, Song HR, Matsui Y, Sakazume S, Yamada M, Narumi Y, Alanay Y, 
Unger S, Cho TJ, Park SS, Ikegawa S, Meinecke P, Superti-Furga A. A variant of Desbuquois 
dysplasia characterized by advanced carpal bone age, short metacarpals, and elongated 
phalanges: report of seven cases. Am J Med Genet A. 2010;152A(4):875-85 
 
7. Balasubramanian K, Li B, Krakow D, Nevarez L, Ho PJ, Ainsworth JA, Nickerson DA, 
Bamshad MJ, Immken L, Lachman RS, Cohn DH. MED resulting from recessively inherited 
mutations in the gene encoding calcium-activated nucleotidase CANT1. Am J Med Genet A. 
2017;173(9):2415-2421. doi:10.1002/ajmg.a.38349 
 
8. Nizon M, Huber C, De Leonardis F, Merrina R, Forlino A, et al Further Delineation of CANT1 
Phenotypic Spectrum and Demonstration of Its Role in Proteoglycan Synthesis. Hum Mutat 
2012; 33(8): 1261–1266. 
 
9. Bui C, Huber C, Tuysuz B, Alanay Y, 1 Mutations in Desbuquois Dysplasia Type 2. Am J Hum 
Genet. 2014 Mar 6; 94(3): 405–414. 
 
10. Parry DA, Holmes TD, Gamper N, et al. A homozygous STIM1 mutation impairs store-
operated calcium entry and natural killer cell effector function without clinical 
immunodeficiency. The Journal of Allergy and Clinical Immunology. 2016;137(3):955-957.e8. 
doi:10.1016/j.jaci.2015.08.051. 
 
11. Byun M, Abhyankar A, Lelarge V, et al. Whole-exome sequencing-based discovery of STIM1 
deficiency in a child with fatal classic Kaposi sarcoma. The Journal of Experimental Medicine. 
2010;207(11):2307-2312. doi:10.1084/jem.20101597. 
 
12. Fuchs S, Rensing-Ehl A, Speckmann C, et al. Antiviral and regulatory T cell immunity in a 
patient with STIM1 deficiency. Journal of Immunology (Baltimore, Md : 1950). 
2012;188(3):1523-1533. doi:10.4049/jimmunol.1102507. 
 
13. Schaballie H, Rodriguez R, Martin E, Moens L, Frans G, Lenoir C, Dutré J, Canioni D, 
Bossuyt X, Fischer A, Latour S, Meyts I, Picard C. A novel hypomorphic mutation in STIM1 
results in a late-onset immunodeficiency. J Allergy Clin Immunol. 2015;136(3):816-819.e4. 
doi: 10.1016/j.jaci.2015.03.009 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14. Wang S, Choi M, Richardson AS, Reid BM, Seymen F, Yildirim M, et al. STIM1 and SLC24A4 
are critical for enamel maturation. J Dent Res 2014;12:94S-100S.  
 
15. Maus M, Jairaman A, Stathopulos PB, Muik M, Fahrner M, Weidinger C, Benson M, Fuchs S, 
Ehl S, Romanin C, Ikura M, Prakriya M, Feske S. Proc Natl Acad Sci U S A. Missense 
mutation in immunodeficient patients shows the multifunctional roles of coiled-coil domain 3 
(CC3) in STIM1 activation. 2015;112(19):6206-11 
 
16. Canna SW, Goldbach-Mansky R. New monogenic autoinflammatory diseases--a clinical 
overview Semin Immunopathol. 2015;37(4):387-94  
 
17. Lian J, Cuk M, Kahlfuss S, Kozhaya L, Vaeth M, Rieux-Laucat F, Picard C, Benson MJ, 
Jakovcevic A, Bilic K, Martinac I, Stathopulos P, Kacskovics I, Vraetz T, Speckmann C, Ehl S, 
Issekutz T, Unutmaz D, Feske S. ORAI1 mutations abolishing store-operated Ca2+ entry 
cause anhidrotic ectodermal dysplasia with immunodeficiency. J Allergy Clin Immunol. 
2018;142(4):1297-1310.e1 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
Figure 1. Skin desquamation on the palms and nail dystrophy. These pictures were taken following 
initial blistering of the skin  
 
Figure 2. Patient with STIM1 deficiency. A) Mutation segregation (N/A- not available, the genotypes of 
two siblings are not available, but both are healthy and neither have any clinical features to suggest 
STIM1 or CANT1 deficiency). B) Western blot showing expression of STIM1and STIM2 in PBMC from 
HC, P1 and V:2, representative blot from 2 separate experiments, *Non-specific binding C) Calcium 
flux in Patient T cells compared to healthy control (HC). T cells were incubated for 1 hour at 37oC in 
0% CO2 with 2µM fura-2 AM in standard bath solution (SBS) with 0.01% pluronic acid (Invitrogen). 
Cells were seeded at 5x105 cells/well. T cells were stimulated for 90 seconds by either Thapsigargin 
(TG) at 1µM or the TCR was activated by soluble CD3 at 1µg/ml (Clone OKT3). For TCR stimulation 
the plate was coated with anti-CD28 (1µg/ml, Clone CD28.2). Fura-2 was excited at 340 nm and 380 
nm and emission was collected at 510 nm.  Measurements were taken on a 96-well fluorescence 
plate reader (FlexStation III, Molecular Devices)  
 
Figure 3. The image on the left (A) is a DP x-ray of the hand of a normal 5 year old boy. The 
ossification centre of the ulnar epiphysis (ue) is not visible and the scaphoid (S) and trapezium and 
trapezoid (T) ossifications centres are very small. The study was performed following penetrating 
trauma and the density between the middle and ring metacarpal bones is a glass foreign body. 
Compare with the appearances of our patient’s hand on the right (B) where the ulnar epiphysis 
ossification centre is clearly visible and the radial sided carpal bones are nearly fully formed with 
appearances more typical of an 8 or 9 year old boy. C) Xray of thoracolumbar Spine”. It demonstrates 
a gentle scoliosis of the cervicothoracic spine. 
 
Figure 4. Interferon-stimulated gene (ISG) expression in patients’ and healthy controls (HC) 
monocytes. V:2, patients with homozygous pL74P STIM1 mutation. Statistical analysis was carried 
out using two-tailed/unpaired Student’s t-test *p < 0.05  **p < 0.005 and  ***p < 0.0005 
 
Figure 1. Suppl. TCR repertoire as assessed by T receptor spectraphenotyping. The arrow is showing 
a missing Vb7.2 expression on patients’ T cells. 
 
Figure 2. Suppl. A) Phytohaemagglutinin (PHA, 3 differed concentrations 5,10 and 100 g/ml) and 
anti-CD3 T cell proliferation (P1 red 2 separate experiments) Healthy controls (HC black) X3 B) CD69, 
HLA-DR and CD25 expression on T cells form the patient (P1 red) and 3 HC black following 
stimulation with anti-CD3 for 48 hours  
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Table 1 Immunological findings  
 
*Includes patients from Picard et al 2009, Byun et al 2010 and Fuchs et al 2012; **V:2 and V:3 originaly reported by Parry et al in 2015, follow up investigation on the same 
patients reported in this study (2018)*** No immunological findings were available for Wang et al 2014, therefore total number of patients is 12; ↔ Normal; ↓ low; ↑ high;  
Present 
study (P1)
Schaballie et 
al 2015*
Vaeth et 
al 2017
Parry              
et al 2015          
Present study 
(V:2 V:3)**
Summary 
of all 
data***
Lymphocyte count 1/1↔ 8/8↔ 1/1↔ 2/2↔ 2/2↔ 12/12↔
CD3+ 1/1↔ 8/8↔ 2/2↔ 2/2↔ 11/11↔
CD4+ 1/1↔ 8/8↔ 2/2↔ 2/2↔ 11/11↔
CD27+ CD45RA+ (naïve) 1/1↔ 3/4↓ 2/2↔ 3/7↓
CD27+ CD45RA- (memory) 1/1↔ 2/2↑ 2/2↔ 2/5↑
CD27-CD45RA- (memory effector) 1/1↑ 2/2↑ 2/2↔ 3/5↑
CD25+CD127- (Treg) 2/4↓ 2/2↔ 2/6↓
CD8+ 1/1↔ 2/8↓ 1/2↓ 1/2↓ 3/11↓
CD27+ CD45RA+ (naïve) 1/1↔ 2/3↓ 1/2↓ 2/6↓
CD27+ CD45RA- (memory) 1/1↑ 1/2↑ 1/2↓ 2/5↑
CD27- CD45RA- (memory effector) 1/1↔ 1/2↑ 2/2↔ 1/5↑
CD27- CD45RA+ (effector) 1/1↓ 2/3↑ 1/2↑ 3/6↑
CD19+ 1/1↔ 1/8↓ 1/1↔ 1/2↑ 1/2↓ 10/12↔
CD27+ IgM+ IgD+ 1/1↔ 2/2↓ 1/2↓ 2/5↓
CD27+ IgM- IgD- 1/1↔ 1/2↓ 1/2↓ 1/5↓
CD27- IgM+ IgD+ 1/1↔ 1/2↑ 1/2↑ 1/5↑
CD56+ CD16+ (NK cells) 1/1↔ 8/8↔ 1/1↔ 2/2↔ 2/2↔ 12/12↔
Tcell Vbeta repetoire 1/1↔ 1/2↔ 2/2↔ 2/5↔
T lymphocyte proliferation test
PHA 1/1↔ 5/5↓ 1/1↓ 2/2↔ 6/9↓
Anti CD3 1/1↔ 5/5↓ 2/2↔ 5/8↓
Tetanus toxoid 1/1↓ 1/1↓
VZV 1/1↓ 1/1↓
IgG 1/1↔ 3/8↑ (2/8↓) 2/2↔ 2/2↔ 3/11↑
IgA 1/1↔ 2/8↑ (2/8↓) 2/2↔ 1/2↑ 3/11↑
IgM 1/1↔ 2/8↓ 0/2↓ 2/2↔ 2/11↓
IgE 1/1↑ 3/4↔ 1/2↓ 1/2↓ 1/7↓
Pneumococcal antibody response 1/1↔ 1/2↓ 2/2↔ 2/2↔ 1/4↓
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 Table 2 Clinical features of STIM1 deficiency 
 
 
* homozygous; ** age given in years: LOF-Loss of function; LOE-loss of expression; 1-yes; 0 no; AIHA-autoimmune hemolytic anemia; ITP-autoimmune 
thrombocytopenia; LN-lymphadenopathy; H/S- hepatosplenomegaly; NR-not reported   
 
Study Byun et al 2010
Wang et al 
2014
Vaeth et al 2017 Present study Summary 
Patient ID from the study V-1 V-4 V-7 P4 P5 P6 iV:1 P 7 P 8 V2 V3 P1 P1
STIM1 mutation E136X* Not known E136X* 1,538–1G>A* Arg429Cys* Arg429Cys* p.Arg426Cys* p.165P>Q* p.165P>Q* p.L74P* p.L74P* p.L374P* p.Ser160fs*
Predicated protein 
effect 
LOE N/A LOE LOE LOF LOF LOF LOE/LOF LOE/LOF LOE/LOF LOE/LOF LOF LOE/LOF
Age at last 
examination**
9 1.5 6 2 6 1.7 6 21 8 11 21 22 4
Immunodeficiency 1 1 1 1 1 1 0 1 1 0 0 1 1 10/13
Immune 
dysregulation
AIHA, ITP,                     
LN, H/S
AIHA, ITP,                     
LN, H/S
ITP
AIHA , LN                  
H/S
AIHA                        
ITP
AIHA                         
ITP
0 LN , H/S 0 0
Transient           
ITP
0 0 8/13
Muscular 
hypotonia/weaknes
1 1 1 0 1 1 0 1 1 0 0 1 1 9/13
Mydriasis 1 1 1 0 1 1 0 0 0 0 0 NR 1 6/12
Anhydrosis NR NR NR 0 1 1 0 1 0 1 1 1 1 6/10
Enamel 
hypoplasia/defect 
1 0 0 0 1 1 0 1 1 1 1 1 1 9/13
Died 1 1 0 1 0 1 0 0 0 0 0 0 0 4/13
Alive 0 0 1 0 1 0 1 1 1 1 1 1 1 9/13
Skin involvement 0 0 0
Eczematous 
lesions           
fingers and feet 
Generalised        
eczema 
Severe                 
eczema
0 Psoriasis 
Chronic             
dermatitis
Mild                 
eczema
0 0
Atypical 
eczema 
ichythosis, 
7/13
GI involvement 0 0 0 0  Colitis 0 0 Colitis 0 0 0 0 0 2/13
Nail involvement 0 0 0 0  Nail dysplasia 0 1 0 Brittle nails 0 0 0
Nail 
dystrophy
3/13
Parry ey al 2015 Picard et al 2009 Fuchs et al 2012 Schaballie et al 2015
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